A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines
Completed · Phase 3 · NCT05248880
Conditions: Glabellar Lines
At a glance
- Research payments reported, 2025
- $3,758
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 309
About the trial
- Sponsor
- AbbVie
- Tested
- AGN-151586 (drug), Placebo (drug)
- Dates
- Started 2022-03-08; completion 2023-02-01
- Results posted
- Yes
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. AGN-151586 is an investigational product being developed for the treatment of GL. The purpose of this study is to evaluate the safety and efficacy of AGN-151586 for the treatment of GL in toxin-naïve participants with moderate to severe GL. This is a 12 week study in which eligible subjects will be enrolled into the study containing 2 treatment periods, double-blind period and open-label period. Participants are randomly assigned to receive AGN-151586 or placebo. There is 1 in a 4 chance that part…
From ClinicalTrials.gov, last updated 2026-02-18. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $3,758 in research payments for this study in 2025 (1 payments).
Products named: Botox
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Skin Dc PLLC $3,758
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.